Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Cormorant Asset Management, LP
Form 13F · Q2 2026

Cormorant Asset Management, LP

CIK 1583977Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$2.0B
Reported book value
50
Positions
12
Quarters on record
Top 50
Positions

Cormorant Asset Management, LP — holdings

Top 50 positions of 50, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1PRAX Praxis Precision Medicines I640,000−27.7%$214M11.0%
2BBOT Bridgebio Oncology Therapeut17.9M+0.0%$136M7.0%
3PBLS Parabilis Medicines Inc4.6M—$126M6.5%
4RAPP Rapport Therapeutics Inc2.7M−10.1%$111M5.7%
5ERAS Erasca Inc6.0M+3.4%$110M5.6%
6EWTX Edgewise Therapeutics Inc2.5M−23.0%$102M5.2%
7EYPT Eyepoint Inc7.0M−15.3%$100M5.1%
8ALMS Alumis Inc3.3M−16.8%$92M4.7%
9ABIVAX SA Abivax Sa675,000−11.2%$90M4.6%
10DNTH Dianthus Therapeutics Inc750,000−21.1%$73M3.7%
11DRUG Bright Minds Biosciences Inc900,000−15.0%$63M3.2%
12MLTX Moonlake Immunotherapeutics3.2M−28.5%$62M3.2%
13BIOA Bioage Labs Inc2.4M−17.3%$59M3.0%
14ORKA Oruka Therapeutics Inc533,340+0.0%$51M2.6%
15ANL Adlai Nortye Ltd4.0M+37.3%$46M2.3%
16BBIO Bridgebio Pharma Inc550,000−35.3%$41M2.1%
17TNGX Tango Therapeutics Inc1.3M−8.8%$41M2.1%
18BHVN Biohaven Ltd2.6M+48.3%$39M2.0%
19AGMB Agomab Therapeutics Nv2.5M+0.0%$32M1.6%
20MBX Mbx Biosciences Inc550,000−50.9%$30M1.6%
21CLYM Climb Bio Inc2.1M—$27M1.4%
22OLEMA PHARMACEUTICALS INC Olema Pharmaceuticals Inc2.1M−44.9%$27M1.4%
23DMRA Damora Therapeutics Inc1.0M−34.4%$26M1.3%
24PHVS Pharvaris N V750,000−25.0%$26M1.3%
25CRBP Corbus Pharmaceuticals Hldgs2.3M+0.0%$22M1.1%
26SYRE Spyre Therapeutics Inc225,000—$20M1.0%
27DFTX Definium Therapeutics Inc400,000—$19M1.0%
28NAMS Newamsterdam Pharma Company500,000−47.4%$17M0.9%
29ROIV Roivant Sciences Ltd475,000−36.7%$17M0.9%
30CABA Cabaletta Bio Inc5.0M−9.1%$16M0.8%
31HLXC Helix Acquisition Corp Iii1.3M+0.0%$14M0.7%
32ASND Ascendis Pharma A/S50,000—$13M0.7%
33KLRA Kailera Therapeutics Inc550,000—$12M0.6%
34INSM Insmed Inc75,000−60.5%$8M0.4%
35FTH Faeth Therapeutics Inc1.0M+235.8%$8M0.4%
36ELVN Enliven Therapeutics Inc150,000—$8M0.4%
37TARS Tarsus Pharmaceuticals Inc100,000−55.6%$6M0.3%
38IBIO Ibio Inc3.6M—$6M0.3%
39CRINETICS PHARMACEUTICALS IN Crinetics Pharmaceuticals In125,000−50.0%$5M0.2%
40ARQT Arcutis Biotherapeutics Inc175,000−61.1%$5M0.2%
41ARWR Arrowhead Pharmaceuticals In50,000−50.0%$4M0.2%
42GPCR Structure Therapeutics Inc75,000−57.1%$4M0.2%
43RACC Research Alliance Corp Iii370,000—$4M0.2%
44COGT Cogent Biosciences Inc100,000−50.0%$4M0.2%
45ALT Altimmune Inc1.2M—$4M0.2%
46AMLX Amylyx Pharmaceuticals Inc200,000−42.9%$4M0.2%
47ODTX Odyssey Therapeutics Inc175,000—$3M0.2%
48PCVX Vaxcyte Inc50,000−50.0%$3M0.1%
49BOLD Boundless Bio Inc1.0M—$2M0.1%
50QUINCE THERAPEUTICS INC Quince Therapeutics Inc5,498—$100,0090.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.